Low-grade systemic inflammation is an independent risk factor for psoriasis, especially moderate to severe disease, results ...

Residents say the toxic air also causes skin rashes and eye irritation, damages crops, and restricts routine tasks like drying laundry outdoors. "Everything is covered with dust or soot," said ...

In the Phase III ICONIC-LEAD trial, 75% of adolescents with moderate-to-severe plaque psoriasis treated with icotrokinra achieved completely clear skin by week 24. Results from the Phase III ...

Claim your 7-day free trial now. Protagonist Therapeutics, Inc. PTGX on Thursday announced new data for a pill that treats moderate-to-severe plaque psoriasis. The Phase 3 study was conducted in ...

Icotrokinra appears to be an effective treatment for adolescent patients with moderate to severe plaque psoriasis, according to a subgroup analysis of the ICONIC-LEAD study. The randomized ...

Icotrokinra achieved 75% complete skin clearance in adolescents with moderate to severe plaque psoriasis by week 24, indicating significant efficacy. The ICONIC-LEAD trial is the first to evaluate ...

Many people who have psoriasis will experience the telltale sign of itchiness or burning. But for people with differing skin tones, that’s where the similarities may end. The symptoms of ...

Art Garfunkel is breaking the sound of silence around his experience with plaque psoriasis. The singer, one half of the folk-rock duo Simon & Garfunkel, has teamed with Sun Pharma to discuss how ...

A group of researchers have created four novel laboratory-developed tests that can distinguish between and subclassify atopic dermatitis and psoriasis in a skin biopsy, according to a press release.

Patients with moderate to severe psoriasis treated with ustekinumab and guselkumab showed a trend towards a lower risk for herpes zoster (HZ) and postherpetic neuralgia (PHN) than those receiving ...